e-learning
resources
Barcelona 2013
Tuesday, 10.09.2013
COPD treatment
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Efficacy of administration of 0.02% solution of decamethoxine via nebulizer in patients with infectious exacerbations of COPD
O. Denysova, R. Sukhin (Kyiv, Ukraine)
Source:
Annual Congress 2013 –COPD treatment
Session:
COPD treatment
Session type:
Thematic Poster Session
Number:
3669
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
O. Denysova, R. Sukhin (Kyiv, Ukraine). Efficacy of administration of 0.02% solution of decamethoxine via nebulizer in patients with infectious exacerbations of COPD. Eur Respir J 2013; 42: Suppl. 57, 3669
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Roflumilast added to triple therapy in severe COPD patients with frequent exacerbations: Efficacy and tolerability
Source: International Congress 2014 – Markers
Year: 2014
Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013
Compare clinical effectiveness of various types of bronchodilators in COPD patients
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
Efficacy of roflumilast with concomitant cardiovascular medication in patients with COPD
Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management
Year: 2013
A self-treatment programme in patients with COPD: Effectiveness for the reduction of severe exacerbations
Source: International Congress 2015 – Latest insights into chronic care
Year: 2015
Mukoregulatory drugs in treating COPD
Source: International Congress 2014 – Predictors
Year: 2014
Impact of mucolytic treatment on COPD exacerbations
Source: Annual Congress 2013 –Cell biology and murine models of asthma and inflammation
Year: 2013
Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
Erdosteine improves airflow in patients with severe exacerbation of COPD (AECOPD)
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
Real life assessment of inhaler use and acute exacerbations in 2935 COPD patients
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
A pilot study of CPAP therapy for excessive dynamic airway collapse during acute exacerbation of COPD
Source: International Congress 2014 – COPD - from biomarkers to novel therapeutic opportunities
Year: 2014
High-dose N-acetylcysteine in the prevention of COPD exacerbations: Results of the PANTHEON study
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Frequency of COPD exacerbations and severity of COPD
Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations
Year: 2013
Recording and response to hyperglycaemia in patients presenting with infective exacerbations of COPD
Source: Annual Congress 2013 –Difficult and rare respiratory infections
Year: 2013
Screening eosinophil counts and risk of exacerbations after inhaled corticosteroid withdrawal in severe COPD
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
The effect on mortality of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A focus on the frequent exacerbator phenotype
Source: International Congress 2015 – COPD and lung function: risk factors and outcomes
Year: 2015
Characterization of readmissions in patients hospitalized with COPD exacerbation
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
Efficacy of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) on exacerbations and health status in GOLD Group D COPD patients: The FLAME study
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept